Send feedback

TP53 p.Lys120Ter

c.358A>T · rs121912658 · VCV12363

Pathogenic Single submitter
Classification
Pathogenic
ClinVar
Review
Single submitter ★☆☆☆
ClinVar · 2 submitters
Consequence
nonsense (stop-gain)
predicted LoF
gnomAD v4.1
Not reported
no allele count reported in gnomAD v4.1 (AN 1,612,268)
Conditions
2
hereditary neoplastic syndrome

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
Consequencenonsense (stop-gain)predicted loss-of-function in a haploinsufficient gene (ClinGen)
NMDpredictedpremature termination codon in exon 4 of 11
Splicing
SpliceAI—not assessed · no allele here is in the release
PangolinΔ0.23loss · gain 0.00 · not in the SpliceAI release · independent
Constraint at this position
ConservationphyloP 7.9GERP 2.2, phastCons 1
Overall
CADD38.0PHRED · no single calibrated threshold — expert panels disagree

Predicted loss-of-function is descriptive, not an applied PVS1 code.

Population frequency

gnomAD v4.1 · exomes + genomes

No allele count reported in gnomAD v4.1 (AN 1,612,268). This is missing data, not an absence: the variant may or may not be present in gnomAD. Rarity (ACMG PM2) and BA1/BS1 cannot be assessed for it.

Variant & gene context

Gene
TP53
Protein
p.Lys120Ter
Coding
c.358A>T
MANE Select
NM_000546
dbSNP
rs121912658
Type
single nucleotide variant
Location
chr17:7676011 (GRCh38)
Gene constraint
LOEUF 0.449 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
Structure
AlphaFold pLDDT 75.83 · 321 PDB
Residue 120
a DNA-binding region; the 'interaction with axin1' region; a β-strand; the 'interaction with ccar2' region; a UniProt-annotated variant site (in sporadic cancers; somatic mutation; abolished acetylation; impaired ability to induce proapoptotic program; mimics lactylation, leading to decreased ability to undergo liquid-liquid phase separation and activate the transcription factor activity); a UniProt-annotated variant site (in sporadic cancers; somatic mutation); a UniProt-annotated variant site (in a sporadic cancer; somatic mutation; mimics lactylation, leading to decreased ability to undergo liquid-liquid phase separation and activate the transcription factor activity); a functional site (interaction with dna); a modified residue (n6-acetyllysine); a modified residue (n6-lactoyllysine); the 'interaction with hipk1' region; the 'required for interaction with znf385a' region; the 'required for interaction with fbxo42' region
Full TP53 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/tp53-p-lys120ter (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown